EvidentIQ Group strengthens its position in oncology through the acquisition of asthenis

EvidentIQ, 21 Sep 2023

EvidentIQ, an international provider of clinical trial software, has completed the acquisition of a majority stake in asthenis GmbH, the market leader in cancer documentation software in Germany and Switzerland. Marcus van den Bergh, founder of asthenis, will continue to support the company and its customers in his role as managing director and shareholder.

asthenis was founded as one of the pioneers in its segment in 1997 and today serves almost 300 leading oncology clinics with its solutions. In addition to legally compliant documentation of all cancer entities, the browser-based software ODSeasyNet provides doctors with additional functions such as the creation of doctor's letters, automatic cancer registry reporting or support in follow-up care management. With the newly developed product ODS-TumorBoard, asthenis has also recently begun offering independent tumor conference software tailored to the needs of oncology, which supports practitioners in making therapy decisions and meets all the requirements of the German Hospitalization Act (Krankenhauszukunftsgesetz).

asthenis will significantly expand the services offered by EvidentIQ in the field of oncology. In the future, doctors will be informed about current studies on the basis of anonymized patient data. Furthermore, asthenis will contribute its expertise in the collection of real world evidence data in the field of oncology, i.e. the collection of treatment results from the general population for the purpose of benchmarking against specific studies.

Marcus van den Bergh, managing director of asthenis: „We are very pleased that we are well positioned for the future with BID Equity and the EvidentIQ Group as investors. For our customers, this means that the accustomed level of quality will continue to be reliably delivered and the resources for new innovations are available. We look forward to working together.“

Dr. Dominique Manu, Managing Director EvidentIQ Group: "With the acquisition of asthenis, EvidentIQ Group adds another company that is one of the absolute technology specialists and market leaders in its niche. With this step, we expand our expertise in the oncology field and are able to better tailor the synergies from our product and service portfolio in real world evidence and data-driven study execution for our customers."


BID Equity Fund III closes at the hard cap of EUR 310 million – targeting software companies


JustRelate acquires Bmobile/Dartagnan to expand DXP product portfolio and European market position

More EvidentIQ news

15 Jun 2022

EvidentIQ, a pioneering provider of end-to-end eClinical solutions, and Dacima Software Inc. of Montréal, a leading provider of data management software solutions for clinical trials, have signed an agreement that will result in the acquisition of Dacima.

04 Feb 2021

BID Equity Fund II, a fund advised by BID Equity, acquires Fortress Medical Systems, the US-based vendor of Clindex®, an integrated CTMS and EDC system.

25 Jan 2021

BID Equity Fund II, a fund advised by BID Equity, acquires France-based Carenity, an anlytics platform supporting +500,000 patients and caregivers worldwide.

12 Sep 2019

BID Equity Fund II, a fund advised by BID Equity, acquires a majority stake in XClinical GmbH. XClinical is a leading international provider of software solutions for drug and medical device studies.